chrisvoncsefalvay/vaers-outcomes huggingface dataset:
It started with sore throat days 2-5 I had a dry cough and a low grade fever and congestion, I got the regeneron treatment and felt better within 3 days.
after dose administered patient  started feeling anxious after 15 minutes, he felt his heart racing ,blood pressure was elevated, felt nauseous, and had chills
Vasovagal Patient at reception desk to schedule follow up appointment and stated "uh-oh".  Patient immediately collapsed, losing consciousness ofor less than 60 seconds.  Did hit posterior right head on floor in lobby.  Site actively bleeding.  Patient denies chest pain or shortness of breath.  Reports feeling  Very dizzy and light headed.  Complaining of headache.  Unable to rate head pain.  Denies cervical pain.  Alert and oriented x 3.  Reports he hadn't eaten since yesterday.  Feeling nauseated.  Pale in color.
First vaccine of Covid19-BIVALENT, Provider not relized can not be given as initial  NO ADVERSE EFFECT TO PATIENT.
Information has been received from a health professional concerning a 4 year old female who on 01/21/1998 was vaccinated with the first dose of varicella vaccine SC in the right thigh. Concomitant therapy that same day included the first dose of MMR vaccine SC in the left thigh. On 12/17/2001, it was reported that the pt "now" has chicken pox. According to the nurse, the pt had an appointment to be seen that day at the office, but it "certainly sounds like chicken pox" with over 200 lesions. Follow-up info from the health professional noted that on 12/15/2001, the pt's father called to report that the pt had pimple like spots all over her body especially legs, back and stomach. It was noted that there were blisters on her back that never broke open and leg pimples never blistered. There was very little itching. The pt was afebrile. It was noted that the pt had been exposed "a few weeks ago" to chicken pox and had an ear infection with fever one week prior to this event. The pt was not seen at this time by a doctor. Subsequently, the pt had an uneventful recovery. No further info is available.
Almost immediately after I received my dose, I felt very dizzy and began sweating profusely. My vision became very blurry, and I had trouble breathing. No one came to check and see if I was ok. They just waved me out of the building, being terrified of what was going on and what wanting to leave the facility I drove out into the parking lot for the additional assessment. In the parking lot, I continued panting and sweating, feeling as though I was going to vomit. Again, no one checked on me, and I was too incapacitated to "honk my horn 3 times." After the additional 15 minutes, they waved everyone through to leave, so I left. There was no professional around to speak with at this point anyways. Covered in sweat and dizzy. I drove home to go to bed.  When I got home about 10 minutes later, my arm where I received the vaccine was already very sore. I laid in bed and fell asleep and continued sleeping off and on for the rest of the day and night. My shoulder was still sore the following morning when I woke up. As the day progressed my fatigue increased (Sunday was not too bad.) Monday (3.22.21) I felt terrible, (headache, brain-fog, bad back pain, bad knee pain, bad hip pain.) My symptoms have persisted all week. I am unsure as to what to do. I do not have a doctor that I regular see. I am afraid to receive another dose and have even worse reactions/side-effects
This spontaneous prospective pregnancy report as received from a medical assistant, for GARDASIL, a Pregnancy Registry product, concerning a 31 years old female patient. The patient's history of previous pregnancies and live births is not known. The patient was vaccinated IM. with first dose of, 0.5 ml GARDASIL (lot number reported as "0518AE", expired date 21-NOV-2014) on 25-SEP-2012. No other co-suspects were reported. No concomitant medications were reported. The patient was pregnancy before getting the vaccine. Initial exposure to GARDASIL was at 28 week(s) gestation. The patient's LMP was on approximately 13-MAR-2012 and EDD was on approximately 18-DEC-2012. The patient was exposed to GARDASIL during trimester 3. No treatment information was performed. The outcome of the patient was unknown. Additional information has been requested.
Excessive bleeding and swelling at site of injection immediately after IM injection upper left deltoid muscle about 3:15 PM on May 15, 2022.  Changed dressing to 2 standard bandages along with ice pack application for 15 minutes. Patient did NOT have dizziness, faintness nor abnormal pain. Patient received Adacel immunization in right upper deltoid minutes prior without any observed reactions. Patient remaind seating for 15 minutes with daughter and left with out complaint thereafter.
This case was reported by a physician via sales rep and described the occurrence of shingles in a 84-year-old female patient who received SHINGRIX (batch number 9YD45, expiry date unknown) for prophylaxis. Previously administered products included ZOSTAVAX (received previously more than 10 years before the reporting date). On 26th June 2018, the patient received SHINGRIX .5 ml. On 26th June 2018, less than a day after receiving SHINGRIX, the patient experienced sciatica. On an unknown date, the patient experienced shingles and contusion. On an unknown date, the outcome of the shingles, sciatica and contusion were unknown. It was unknown if the reporter considered the shingles, sciatica and contusion to be related to SHINGRIX. Additional details were provided as follows: The patient received SHINGRIX vaccine on the left deltoid. The patient thought getting sciatica on the day of SHINGRIX vaccination or day before SHINGRIX vaccine administration. A few days after SHINGRIX vaccine administration, the patient believed getting bruise in buttocks. The patient came back to office and clearly had mild case of shingles on her left buttocks and down leg. The physician was unclear if the patient had case of shingles occurring prior to or because of SHINGRIX vaccine. The physician was unclear if events were related to SHINGRIX. The reporter agreed to follow up.
A non-serious spontaneous report of administration of expired product was received from a health professional concerning a four-year-old male patient. Neither relevant medical history nor concomitant medications have been reported for this patient. The vaccine expired on 09-Jan-2011. The patient received the expired FLUMIST on 10-Jan-2011. There was no adverse event associated with this medication error; therefore, treatment and reporter causality assessments are not applicable, and the event is considered resolved. This case will be submitted in accordance with MedImmune's FLUMIST post-marketing commitment for the indicated population of 2 years to 59 months of age. Additional information was received on 11-Mar-2011 and incorporated into the narrative: There were no late occurrence of adverse events.
No additional AE reported.; PEDVAXHIB has been administered to the patient after the excursion occ; This spontaneous report was received from a nurse prescriber and refers to a patient of unspecified age and gender. The patient's concomitant medications, pertinent medical history, concurrent conditions, drug reactions or allergies were not reported.  On an unknown date, the patient was vaccinated with improperly stored dose of haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) intramuscular injection, 0.5 ml, lot #U024090, expiration date: 28-OCT-2023 (vaccination schedule, anatomical location and route of administration were not provided) for prophylaxis (product storage error). Temperature excursion evaluation was not performed at the time of the call. The complete cumulative time and temperature details are unknown until the customer returns the multiple excursion form that was submitted to her. No additional adverse event was reported.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2207USA007323: US-009507513-2207USA007365: US-009507513-2207USA007382: US-009507513-2207USA007383: US-009507513-2207USA007612: US-009507513-2207USA007630: US-009507513-2207USA007632:
I AM A FEMALE 65 YEARS OLD. I HAVE HAD LESS THAN 10 HEADACHES IN MY ENTIRE LIFE. I HAVE HAD A DULL HEADACHE FOR 3 WEEKS. THE HEADACHE IS NOT SHARP, BUT IT IS PERSISTANT. IT NEVER GOES AWAY. I HAVE A HEADACHE FOR 3 WEEKS SINCE RECEIVING THE J & J VACCINE, MARCH 7, 2021.
After about 4 hours of having the shot, I got extremely light headed and nauseous. About the same time I got really bad chills and was shaking aggressively from the cold and got very bad pain in my joints, back, neck and injection site. My skin felt very sensitive and hurt to touch.  I took medication and felt a little better but was unable to eat due to the nausea. A few hours later I still had very sensitive skin and nausea but I was very hot and couldn?t cool off. The following morning at about 8am on April 9 I woke up with hives on my ears, back of my neck up to the top of my head and the center of my chest. I still had severe body pains and my hives spread throughout the day to my face, inflating my forehead, nose and lips. I was still unable to eat because of the nausea and I was still taking ibuprofen which usually eliminates my hives. My body pain, nausea and hives stayed consistent the entire day despite taking the proper medication precautions. At about 12:30am on April 10 I checked my temperature at 100.3 degrees. At 2:30am it dropped to 98.9 degrees. The first meal I was able to eat was at about 7:30am on April 10 while take over the counter anti-nausea medication. It?s currently about 5:15pm on April 10 and most of my hives have reduced to redness, my body pain and injection site pain is still consistent and my nausea has barely reduced.
shingrix vaccine was in bag with covid-19. gave vaccine to patient. Called him and informed him of mistake. Told him to get covid-19 vaccine in 2 weeks
headache; sore arm; dizziness; This is a spontaneous report from a contactable consumer (patient). A 49-year-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection; Batch/Lot number: ER8735, Expiration date was not reported), via an unspecified route of administration (administered on the right arm) on 21Apr2021 10:30 (at the age of 49-years-old) as 2nd dose, single dose for COVID-19 immunisation. Medical history included sulfa drugs and avocado allergy both from an unknown date. Concomitant medication included multivitamin taken for an unspecified indication, start and stop dates were not reported. Prior to vaccination, the patient has not been diagnosed with COVID-19. The patient didn't receive any other vaccines within 4 weeks prior to COVID vaccine. On an unspecified date, the patient experienced headache, sore arm, and dizziness. It was reported that the patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection; Batch/Lot number: ER8734, Expiration date was not reported), via an unspecified route of administration (administered on the left arm) on 31Mar2021 10:00 (at the age of 49-years-old) for COVID-19 immunisation and experienced severely dizzy, continued for 2.50 weeks 24/7. The only time she felt ok was laying down.  It started to get better in time for her second dose.  After second dose it didn't get worse.  Only a headache in the middle of the night and a sore arm for about a week.  The dizziness has not gone away completely. The adverse events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination the patient has not been tested for COVID-19. Therapeutic measures were taken as a result of the events included meclizine. The outcome of the events was recovered with sequels.    No follow-up attempts are possible. No further information expected.
Patient tested positive for COVID/infection of the lungs; This is a spontaneous report from a contactable consumer. An 81-Year-Old female consumer (patient) reported for herself that she received 1st dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on 04Mar2021 for COVID-19 immunisation. Medical history and concomitant drugs were not provided. The patient was supposed to get the 2nd dose on 25Mar2021 - Patient tested positive for COVID on 14Mar2021 due to exposure to her husband who has COVID infection (husband age: 80 something according to her wife; Tested positive for COVID on 11 Mar2021) - She received an antibody infusion due to infection of the lungs - She was not able to get the 2nd dose since she was advised to wait 90 days before getting the 2nd dose. The outcome of the event was unknown.  Information on the lot/batch number has been requested.
Raised erythemic area on (L) upper arm Cephalexin 500 mg TID x 10 days given Prednisone 20 mg 2 po QD x 5 days.
Information has been received from a pharmacist referring to a patient of unknown age and gender. The patient's pertinent medical history and drug reactions/allergies were not reported. Concomitant therapies included PREVNAR in "2013 and 2015". In "2005", the patient received her first dose of PNEUMOVAX 23 (intramuscular, strength, dose, frequency, batch/lot # and expiration date were not reported) for prophylaxis. On 13-SEP-2018 the patient might have received a second dose of PNEUMOVAX 23 (intramuscular, strength, dose, frequency, batch/lot # and expiration date were not reported.
anaphylactic reaction; This is a spontaneous report received from contactable reporter(s) (Other HCP). Other Case identifier(s): 2022NVX-US-000003483.  A female patient received BNT162b2 (BNT162B2), in Dec2020 as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ANAPHYLACTIC REACTION (medically significant), outcome "unknown". She did not complete her series.   The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: The reported anaphylactic reaction was likely related to BNT162b2 due to temporal relationship and known safety profile of this product.
Left calf /leg was swelling, burning pain that would not stop. Called orthopedic doctor to see if my sprained foot would be causing this and they sent me to hospital for ultrasound on my leg to see if I had a blood clot. After ultrasound they found I had 3 DVT blood clots in my lower left leg. They put me on blood thinner for 3 months and I have to go see a Hematologist.
Indigestion and heart burn the following day after 2nd vaccine, to the point I went across the street to urgent care and sat in their parking lot, not knowing if It was a heart attack or indigestion.  After 15 minutes the symptoms subsided and I was able to leave. Both symptoms will still occur occasionally today which I treat with Tums.  Prior to the vaccine, I have never experienced those symptoms.  I also had loss of taste for exactly 1 week starting the day after the 2nd vaccine.
Day 2- 4 - Sore arm following the injection Day 9 - 14-  Rash at injection site  Day 9 - 13 - swollen lymph node in injection side arm pit Day 13 - Fatigue  Period was shortened to 18 days this cycle.
Severe neuritis (no redness, swelling) but severe lancinating pain down vaccinated arm - sensitive to light touch & pressure Tx with Acyclovir 800 5x /d, NEURONTIN 300 qd VICODIN prn.
On 7 April, approx 9AM, pt. experienced a TIA (Transient Ischemic Attack or Mini-stroke).  Siblings became aware by 10:30, and by 11:45 he was at the ER.  His speech was extremely restricted and he was barely able to speak a few words.  Face was partially asymmetric, but gross and fine motor skills basically unaffected.  He could walk and write his name, follow commands to move arm and legs.  Underwent multiple tests including CAT scan, when no sign of bleed stroke confirmed.  At admittance, Stroke Scale score = 4.  By 3PM, speech started to return, and continued to return.  Continued tests with EEG, EKG, and TTE, but no source for TIA could be pinpointed. Unable to perform MRI due to embedded medical device. By next morning speech had almost returned to normal.  No physical restrictions noted on following day.  Discharged 6PM on 8 April.  Doctors unable to explain cause and could not comment on whether related to receiving vaccine a week prior.  Recovery seems to be complete with no negative lasting effects as of 22 April, 2021.
Diarrhea; body felt warm; Chills; Headache; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (Diarrhea), FEELING HOT (body felt warm), CHILLS (Chills) and HEADACHE (Headache) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032M20A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in November 2020.    On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Mar-2021, the patient experienced DIARRHOEA (Diarrhea), FEELING HOT (body felt warm), CHILLS (Chills) and HEADACHE (Headache). The patient was treated with PARACETAMOL (TYLENOL) at a dose of 1 dosage form. On 03-Mar-2021, DIARRHOEA (Diarrhea) had resolved. On 04-Mar-2021, FEELING HOT (body felt warm), CHILLS (Chills) and HEADACHE (Headache) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications reported.
No adverse event; 1st Moderna COVID shot on 2/6/21/ and 2nd shot was administered on 11/19/21; This spontaneous case was reported by a patient and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1st Moderna COVID shot on 2/6/21/ and 2nd shot was administered on 11/19/21) and NO ADVERSE EVENT (No adverse event) in a 22-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect product included non-company product DUPILUMAB (DUPIXENT) for Atopic dermatitis.    Concomitant products included FLUCONAZOLE for an unknown indication.   On 06-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Nov-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient started DUPILUMAB (DUPIXENT) (Subcutaneous) 300 milligram. On 19-Nov-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1st Moderna COVID shot on 2/6/21/ and 2nd shot was administered on 11/19/21). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1st Moderna COVID shot on 2/6/21/ and 2nd shot was administered on 11/19/21) and NO ADVERSE EVENT (No adverse event) outcome was unknown.            This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.   This case was linked to MOD-2021-623820 (Patient Link).
I have fluttering and palpitations in my chest. I went to the doctor and they noticed swollen lymph nodes under my arm and I am awaiting EKG results
5 days after taking the 2nd dose of Moderna vaccine, my neuropathy in feet has got worsen.  I increased the dose of amytryptyline to 40 mg on my recommendation of PCP.  It helped a bit, but I'm not able to walk outside for  exercise etc.
Transverse myelitis; Paralyzed; A young pregnant woman (Patient); 6 months pregnant; This is a spontaneous report from a contactable consumer. This is the second of 2 reports for the second dose. A 37-year-old female patient received the second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration on 01Apr2021 (Lot number was not reported) as single dose for covid-19 immunisation. The patient medical history and concomitant medications were not reported. Historical Vaccine included the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) on an unspecified date as single dose for covid-19 immunisation and experienced myelitis transverse. The patient received the second dose of bnt162b2 on 01Apr2021 and by 03Apr2021 she was "paralyzed". The patient was 6 months pregnant and had a "transverse myelitis" attack after the vaccine. Events outcome was unknown.  Information about lot/batch number has been requested.
approx 1wk p/vax lt shoulder devel pain on flexion & abduction then arm ached for approx 12;
Significant glare; Increase of intraocular pressure/can feel the pressure up; This is a spontaneous report from a non-contactable consumer, the patient.  A female patient of an unspecified age received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), via an unspecified route of administration on 29Dec2020 as a single dose for COVID-19 vaccination. Medical history included glaucoma and the patient was hard of hearing. Concomitant medications were unknown. On an unknown date the patient experienced significant glare and increase of intraocular pressure, the patient can feel the pressure up.  The patient stated that she had her first vaccine for Covid-19 one week ago today (29Dec2020) and her husband is well and just had his the same evening and he has a history of A-Fib and he is absolutely fine, no side effects and the patient could not find any significant side effects until the delayed side effect occurred and her son who is a doctor thinks it's not related to the vaccine but the patient stated she had a history of advanced glaucoma. The patient further stated she called and questioned him about why the patient would have excessive glare that was delayed after the number of days that the patient took her vaccine, which was 7 days ago, and it was yesterday, and today is better. The patient was due to go back Friday the 15th to receive the second dose of the Pfizer Vaccine, and the patient cannot find information related to the vaccine with advanced glaucoma or increase of IOP (intraocular pressure), the patient was inquiring if she should return for the full dose or maybe the half dose. The clinical outcome of the glare and increase of intraocular pressure was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Vomited, nauseated, dizzy, shortness of breath, cold, drop in BP 99/70. Laid patient down, took BP, wait 5 minutes, gave water and called ambulance.
Information has been received from a 65 year old female with asthma who on 26-Aug-2008 was vaccinated with a dose of ZOSTAVAX. concomitant therapy included cyanocobalamin injection, Montelukast sodium, inhalers, losartan potassium and metoprolol succinate. On 26-Aug-2008 after the vaccination, the patient experienced headaches, a severe dry mouth which caused her to be thirsty. the patient's events were recovering. No futher information is available.